Kuros receives FDA 510(k) clearance for extending commercial indications of MagnetOs Putty in the United States
Schlieren (Zurich), Switzerland, December 10, 2018 – Kuros Biosciences (SIX: KURN) today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for extending MagnetOs Putty indications to use as a stand-alone bone graft in extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft extender in posterolateral spine.
- US Food and Drug Administration (FDA) clearance granted for extending the use of MagnetOs Putty as a stand-alone bone graft in extremities and pelvis
- Paves way for commercial expansion into more clinical indications in orthopedic surgery